Jenna Sarvaideo is an Endocrinology/Metabolic physician affiliated with Medical College of Wisconsin. OpenAlex indexes 19 publications with 276 citations (h-index 6); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
9200 W Wisconsin Avenue
Division Of Endocrinology
Milwaukee, WI 532263522
Telephone
414-955-6723Provider last certified this registry record 23 Apr 2026.
Clinical trials
- Coagulation and Fibrinolysis of Estradiol in Transwomen
Sponsor: Medical College of Wisconsin
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year20251 payment
- Novo Nordisk IncProgram year20231 payment
- AbbVie Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Genitourinary & hormones
46.5%Androgen25.7%Xyosted40%Testosterone39%Testosterone Cypionate21%Part D<11 patientsEstrogen20.7%Estradiol46%Estradiol (Twice Weekly)28%Estradiol Valerate26%Part D<11 patientsMetabolism & gastrointestinal
33.6%GLP-1 receptor agonist20.7%Ozempic54%Mounjaro46%Part D<11 patientsSGLT2 inhibitor8.3%Jardiance100%Part D<11 patients+ 1 more class in this area
Cardiovascular
12.9%Aldosterone antagonist (MRA)6.6%Spironolactone100%Part D<11 patientsStatin6.2%Rosuvastatin Calcium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Clinical Impact of New Reference Intervals for the Roche Prolactin II Immunoassay
Journal of the Endocrine Society
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Brett Kissela, MD
Medical College of Wisconsin
Razelle Kurzrock, MD
Medical College of Wisconsin
Mary Horowitz, MD
Medical College of Wisconsin
Reza Shaker, MD
Medical College of Wisconsin
Yousef Saleh Khader
Jordan University of Science and Technology
Jens Juul Holst
University of Copenhagen
Victor Montori, MD
Mayo Clinic
Christos Mantzoros, MD
Harvard Medical School
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”